[SCHEDULE 13G/A] Arrowhead Research Corporation SEC Filing
Avoro Capital Advisors LLC and Behzad Aghazadeh report beneficial ownership of 11,517,441 shares of Arrowhead Pharmaceuticals common stock, representing 8.3% of the outstanding class. The reported position includes 917,441 shares issuable upon exercise of warrants and the percentage is calculated on an aggregate of 138,100,435 shares outstanding as disclosed in the company's quarterly report.
The filing states Avoro holds sole voting and sole dispositive power over these shares and that the holdings are held for investment purposes on behalf of Avoro Life Sciences Fund LLC. The filing notes the report should not be construed as an admission of beneficial ownership for Section 13 purposes.
Avoro Capital Advisors LLC e Behzad Aghazadeh dichiarano la titolarit脿 effettiva di 11,517,441 azioni ordinarie di Arrowhead Pharmaceuticals, corrispondenti al 8.3% delle azioni in circolazione. La posizione segnalata comprende 917,441 azioni emettibili in seguito all'esercizio di warrant e la percentuale 猫 calcolata su un totale aggregato di 138,100,435 azioni in circolazione, come indicato nel rapporto trimestrale della societ脿.
La comunicazione precisa che Avoro detiene il potere esclusivo di voto e il potere esclusivo di disposizione su tali azioni e che le partecipazioni sono detenute a fini di investimento per conto di Avoro Life Sciences Fund LLC. Si sottolinea inoltre che la segnalazione non deve essere interpretata come un'ammissione di titolarit脿 effettiva ai sensi della Sezione 13.
Avoro Capital Advisors LLC y Behzad Aghazadeh informan la titularidad beneficiaria de 11,517,441 acciones ordinarias de Arrowhead Pharmaceuticals, que representan el 8.3% de las acciones en circulaci贸n. La posici贸n comunicada incluye 917,441 acciones que podr铆an emitirse al ejercerse warrants y el porcentaje se calcula sobre un total agregado de 138,100,435 acciones en circulaci贸n, seg煤n consta en el informe trimestral de la compa帽铆a.
La presentaci贸n indica que Avoro ostenta el poder exclusivo de voto y el poder exclusivo de disposici贸n sobre estas acciones y que las participaciones se mantienen con fines de inversi贸n en nombre de Avoro Life Sciences Fund LLC. Se aclara asimismo que la comunicaci贸n no debe interpretarse como una admisi贸n de titularidad beneficiaria a efectos de la Secci贸n 13.
Avoro Capital Advisors LLC鞕� Behzad Aghazadeh電� Arrowhead Pharmaceuticals 氤错喌欤� 11,517,441欤�毳� 鞁れ鞝侅溂搿� 氤挫湢頃橁碃 鞛堨潓鞚� 鞁犼碃頄堨溂氅� 鞚措姅 氚滍枆欤检嫕鞚� 8.3%鞐� 頃措嫻頃╇媹雼�. 鞁犼碃霅� 歆�攵勳潃 鞗岆煱韸� 頄夓偓搿� 氚滍枆霅� 靾� 鞛堧姅 917,441欤茧ゼ 韽暔頃橂┌, 牍勳湪鞚� 須岇偓鞚� 攵勱赴氤搓碃靹滌棎 旮办灛霅� 齑� 138,100,435欤茧ゼ 旮办鞙茧 瓿勳偘霅橃棃鞀惦媹雼�.
鞁犼碃靹滌棎電� Avoro臧� 頃措嫻 欤检嫕鞐� 雽�頃� 雼弲 鞚橁舶甓� 氚� 雼弲 觳橂秳甓�鞚� 氤挫湢頃橁碃 鞛堨溂氅�, 氤挫湢攵勳潃 Avoro Life Sciences Fund LLC毳� 鞙勴暣 韴瀽 氇╈爜鞙茧 氤搓磤霅橁碃 鞛堧嫟瓿� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 霕愴暅 鞚� 鞁犼碃電� Section 13 氇╈爜靸� 鞁れ鞝� 靻岇湢甓岇潣 鞚胳爼鞙茧 頃挫劃霅橃柎靹滊姅 鞎� 霅滊嫟瓿� 氇呾嫓霅橃柎 鞛堨姷雼堧嫟.
Avoro Capital Advisors LLC et Behzad Aghazadeh d茅clarent d茅tenir la propri茅t茅 b茅n茅ficiaire de 11,517,441 actions ordinaires d'Arrowhead Pharmaceuticals, repr茅sentant 8.3% des actions en circulation. La position d茅clar茅e comprend 917,441 actions susceptibles d'锚tre 茅mises lors de l'exercice de warrants et le pourcentage est calcul茅 sur un total agr茅g茅 de 138,100,435 actions en circulation, comme indiqu茅 dans le rapport trimestriel de la soci茅t茅.
Le d茅p么t pr茅cise qu'Avoro d茅tient le pouvoir exclusif de vote et le pouvoir exclusif de disposition sur ces actions et que les avoirs sont d茅tenus 脿 des fins d'investissement pour le compte d'Avoro Life Sciences Fund LLC. Il est en outre indiqu茅 que la d茅claration ne doit pas 锚tre interpr茅t茅e comme une admission de propri茅t茅 b茅n茅ficiaire aux fins de la Section 13.
Avoro Capital Advisors LLC und Behzad Aghazadeh melden die wirtschaftliche Beteiligung an 11,517,441 Aktien der Stammaktien von Arrowhead Pharmaceuticals, was 8.3% der ausstehenden Aktienklasse entspricht. Die gemeldete Position enth盲lt 917,441 Aktien, die bei Aus眉bung von Warrants auszugeben w盲ren, und der Prozentsatz wurde auf Basis von insgesamt 138,100,435 ausstehenden Aktien berechnet, wie im Quartalsbericht des Unternehmens angegeben.
Die Meldung gibt an, dass Avoro 眉ber alleiniges Stimm- und alleiniges Dispositionsrecht f眉r diese Aktien verf眉gt und dass die Best盲nde zu Anlagezwecken im Auftrag von Avoro Life Sciences Fund LLC gehalten werden. Es wird ferner darauf hingewiesen, dass die Meldung nicht als Anerkennung wirtschaftlicher Eigent眉merschaft im Sinne von Section 13 ausgelegt werden sollte.
- Material stake reported: 11,517,441 shares, representing 8.3% of the class
- Sole voting and dispositive power: Reporting persons state exclusive control over vote and disposition
- Includes warrants: Position incorporates 917,441 shares issuable upon exercise of warrants
- None.
Insights
TL;DR: Avoro reports a material passive stake鈥�8.3%鈥攊n Arrowhead, held with sole voting/dispositive power; position is investment-oriented.
Avoro's reported 11.52 million-share position is above the 5% threshold that typically draws investor attention and could affect float and shareholder composition. The inclusion of 917,441 warrant-derived shares is important because the reported percentage assumes their exercise, which modestly increases the effective stake. The filing identifies the economic owner as Avoro Life Sciences Fund LLC and names Behzad Aghazadeh as portfolio manager, indicating centralized investment decision-making.
TL;DR: This is a significant disclosure for governance monitoring but shows no assertion of control or group action.
The Schedule 13G/A confirms sole voting and dispositive power by Avoro over the reported shares, which simplifies engagement channels for activist or governance-related outreach. The filing explicitly states the securities were acquired and are held in the ordinary course of business for investment purposes and disclaims intent to influence control, which keeps this filing within passive investor norms rather than an active control pursuit.
Avoro Capital Advisors LLC e Behzad Aghazadeh dichiarano la titolarit脿 effettiva di 11,517,441 azioni ordinarie di Arrowhead Pharmaceuticals, corrispondenti al 8.3% delle azioni in circolazione. La posizione segnalata comprende 917,441 azioni emettibili in seguito all'esercizio di warrant e la percentuale 猫 calcolata su un totale aggregato di 138,100,435 azioni in circolazione, come indicato nel rapporto trimestrale della societ脿.
La comunicazione precisa che Avoro detiene il potere esclusivo di voto e il potere esclusivo di disposizione su tali azioni e che le partecipazioni sono detenute a fini di investimento per conto di Avoro Life Sciences Fund LLC. Si sottolinea inoltre che la segnalazione non deve essere interpretata come un'ammissione di titolarit脿 effettiva ai sensi della Sezione 13.
Avoro Capital Advisors LLC y Behzad Aghazadeh informan la titularidad beneficiaria de 11,517,441 acciones ordinarias de Arrowhead Pharmaceuticals, que representan el 8.3% de las acciones en circulaci贸n. La posici贸n comunicada incluye 917,441 acciones que podr铆an emitirse al ejercerse warrants y el porcentaje se calcula sobre un total agregado de 138,100,435 acciones en circulaci贸n, seg煤n consta en el informe trimestral de la compa帽铆a.
La presentaci贸n indica que Avoro ostenta el poder exclusivo de voto y el poder exclusivo de disposici贸n sobre estas acciones y que las participaciones se mantienen con fines de inversi贸n en nombre de Avoro Life Sciences Fund LLC. Se aclara asimismo que la comunicaci贸n no debe interpretarse como una admisi贸n de titularidad beneficiaria a efectos de la Secci贸n 13.
Avoro Capital Advisors LLC鞕� Behzad Aghazadeh電� Arrowhead Pharmaceuticals 氤错喌欤� 11,517,441欤�毳� 鞁れ鞝侅溂搿� 氤挫湢頃橁碃 鞛堨潓鞚� 鞁犼碃頄堨溂氅� 鞚措姅 氚滍枆欤检嫕鞚� 8.3%鞐� 頃措嫻頃╇媹雼�. 鞁犼碃霅� 歆�攵勳潃 鞗岆煱韸� 頄夓偓搿� 氚滍枆霅� 靾� 鞛堧姅 917,441欤茧ゼ 韽暔頃橂┌, 牍勳湪鞚� 須岇偓鞚� 攵勱赴氤搓碃靹滌棎 旮办灛霅� 齑� 138,100,435欤茧ゼ 旮办鞙茧 瓿勳偘霅橃棃鞀惦媹雼�.
鞁犼碃靹滌棎電� Avoro臧� 頃措嫻 欤检嫕鞐� 雽�頃� 雼弲 鞚橁舶甓� 氚� 雼弲 觳橂秳甓�鞚� 氤挫湢頃橁碃 鞛堨溂氅�, 氤挫湢攵勳潃 Avoro Life Sciences Fund LLC毳� 鞙勴暣 韴瀽 氇╈爜鞙茧 氤搓磤霅橁碃 鞛堧嫟瓿� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 霕愴暅 鞚� 鞁犼碃電� Section 13 氇╈爜靸� 鞁れ鞝� 靻岇湢甓岇潣 鞚胳爼鞙茧 頃挫劃霅橃柎靹滊姅 鞎� 霅滊嫟瓿� 氇呾嫓霅橃柎 鞛堨姷雼堧嫟.
Avoro Capital Advisors LLC et Behzad Aghazadeh d茅clarent d茅tenir la propri茅t茅 b茅n茅ficiaire de 11,517,441 actions ordinaires d'Arrowhead Pharmaceuticals, repr茅sentant 8.3% des actions en circulation. La position d茅clar茅e comprend 917,441 actions susceptibles d'锚tre 茅mises lors de l'exercice de warrants et le pourcentage est calcul茅 sur un total agr茅g茅 de 138,100,435 actions en circulation, comme indiqu茅 dans le rapport trimestriel de la soci茅t茅.
Le d茅p么t pr茅cise qu'Avoro d茅tient le pouvoir exclusif de vote et le pouvoir exclusif de disposition sur ces actions et que les avoirs sont d茅tenus 脿 des fins d'investissement pour le compte d'Avoro Life Sciences Fund LLC. Il est en outre indiqu茅 que la d茅claration ne doit pas 锚tre interpr茅t茅e comme une admission de propri茅t茅 b茅n茅ficiaire aux fins de la Section 13.
Avoro Capital Advisors LLC und Behzad Aghazadeh melden die wirtschaftliche Beteiligung an 11,517,441 Aktien der Stammaktien von Arrowhead Pharmaceuticals, was 8.3% der ausstehenden Aktienklasse entspricht. Die gemeldete Position enth盲lt 917,441 Aktien, die bei Aus眉bung von Warrants auszugeben w盲ren, und der Prozentsatz wurde auf Basis von insgesamt 138,100,435 ausstehenden Aktien berechnet, wie im Quartalsbericht des Unternehmens angegeben.
Die Meldung gibt an, dass Avoro 眉ber alleiniges Stimm- und alleiniges Dispositionsrecht f眉r diese Aktien verf眉gt und dass die Best盲nde zu Anlagezwecken im Auftrag von Avoro Life Sciences Fund LLC gehalten werden. Es wird ferner darauf hingewiesen, dass die Meldung nicht als Anerkennung wirtschaftlicher Eigent眉merschaft im Sinne von Section 13 ausgelegt werden sollte.
FAQ
How many Arrowhead (ARWR) shares does Avoro report owning?
What percentage of ARWR does the reported holding represent?
Does the filing include shares from warrants for ARWR?
Who is the economic owner or fund on whose behalf the stake is held?
Does Avoro claim intent to influence control of Arrowhead (ARWR)?
